CytoSorbents Corporation · NASDAQ:CTSO
CytoSorbents — Fact Sheet (2023)
4 slides from CytoSorbents's fact sheet, 2023
Slide 1: Organ Perfusion
Organ Perfusion First CE certified product for cytokine removal in ex-vivo organ perfusion
Slide 2: Organ transplant trends
Organ transplant trends Increasing number of needed organs – decreasing quality of available organs Globally, more than 125,000 organs are transplanted every year. While a transplantation is often the last resort for the patient, organ availability and access remain a problem. An increased life expe
Slide 3: Introducing ECOS-300CY cytokine adsorption
Introducing ECOS-300CY® cytokine adsorption Versatile application in different organs, procedures and platforms The new ECOS-300CY® Therapy is an integrated adsorption system for the dialysis of organ perfusion solutions. It has demonstrated the reliable removal of inflammatory mediators like IL-6,
Slide 4: Contact us today to learn more about the new ECOS-300CY Therapy
Demonstrated removal of inflammatory mediators: IL-6, IL-8, TNF-alpha… Preclinical data proves the efficacy in Steen and Belzer solutions First CE certified product for cytokine removal in ex-vivo organ perfusion Contact us today to learn more about the new ECOS-300CY® Therapy support@cytosorbents.c